secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kyverna Therapeutics, Inc. (KYTX)
CIK:        0001994702
Form:       8-K
Filed at:   2024-05-14T23:59:59+00:00
Accession:  0000950170-24-059613
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kyverna Q1 net loss $26.7M; cash $369.8M; treated 30 patients cumulatively
--------------------------------------------------------------------------

- Net loss of $26.7M ($1.12 per share) vs net loss of $11.1M ($12.10 per share) in Q1 2023.
- Cash, cash equivalents and marketable securities $369.8M as of March 31, 2024, including $336.2M net IPO proceeds.
- Treated 30 patients cumulatively with KYV-101: 8 myasthenia gravis, 7 lupus nephritis, 4 multiple sclerosis.
- KYV-101 granted FDA Orphan Drug Designation for myasthenia gravis; upcoming data at EULAR, ECTRIMS, ACR.
- Net cash used in operations $25.5M in Q1 2024 vs $11.5M in Q1 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1994702/000095017024059613/0000950170-24-059613-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1994702/000095017024059613/kytx-20240514.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-059613

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer